Table 5.
The diagnostic value of autoantibody to CENPF and HSP60 in AFP negative early-HCC.a
| aAb | Cases | AUC value | 95% CI | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|
| CENPF aAb | Early-HCC vs LC + HC + CH | 0.828 | 0.790 to 0.862 | 73.6 | 73.7 | 27.7 | 95.3 |
| Early-HCC vs LC | 0.659 | 0.579 to 0.732 | 73.6 | 37.1 | 37.1 | 73.6 | |
| Early-HCC vs LC + CH | 0.727 | 0.666 to 0.782 | 73.6 | 53.7 | 31.0 | 87.8 | |
| HSP60 aAb | Early-HCC vs LC + HC + CH | 0.779 | 0.737 to 0.817 | 79.3 | 62.2 | 22.8 | 95.5 |
| Early-HCC vs LC | 0.706 | 0.624 to 0.779 | 79.3 | 50.6 | 48.3 | 80.7 | |
| Early-HCC vs LC + CH | 0.706 | 0.643 to 0.765 | 79.3 | 46.0 | 30.7 | 88.0 |
a
aAb: autoantibody; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value. The diagnostic cutoff values of aAb to CENPF and HSP60 were signal intensity of 1152 and 3712 respectively. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis.